Welcome to the e-CCO Library!

P694: COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy.
Year: 2022
Source: ECCO'22
Authors: Ramos Lopez, L.(1);Carrillo-Palau, M.(1);Alonso-Abreu , I.(1);Reygosa, C.(1);Hernández-Buylla, N.(1);Amaral , C.(1);Hernández, A.(1);Benítez-Zafra, F.(1);Pérez-González, F.(1);Quintana-Díaz, H.(1);Hernández-Guerra, M.(1);
Created: Friday, 11 February 2022, 3:56 PM
P694: Disease course during the first five years following diagnosis in a prospective European population-based inception cohort – the ECCO-EpiCom cohort
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Burisch J.*1, Halfvarson J.2, Kupcinskas L.3, Hernandez V.4, Kaimakliotis I.5, Valpiani D.6, Pedersen N.7, Duricova D.8, Kievit L.9, Dahlerup J.F.10, Fumery M.11, Salupere R.12, Arebi N.13, Nielsen K.R.14, Giannotta M.15, Oksanen P.16, Katsanos K.H.17, Vegh Z.18, Ellul P.19, Schwartz D.20, Čuković-Čavka S.21, D'Incà R.22, Turcan S.23, Magro F.24,25,26, Goldis A.27, Langholz E.28, Lakatos P.L.18, Munkholm P.1 EpiCom Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
P694: Genetic predisposition and thiopurine-induced pancreatitis in inflammatory bowel disease patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. Burnet*1, N. de Suray2, B. De Vroey3, P. Hoang4, J-C. Coche5, M. Denis1, J-L. Gala6, O. Dewit1

Created: Friday, 22 February 2019, 9:41 AM
P694: Long-term monitoring of post-surgical recurrence in Crohn's disease using a strategy based on the periodic determination of fecal calprotectin in patients without early postoperative recurrence
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mañosa CiriaPhD, M.(1,2)*;Oller, B.(1);Garcia-Planella, E.(3);Guardiola, J.(4);Cañete, F.(1,2);Gonzalez Muñoza, C.(3);Camps, B.(4);Calafat, M.(1,2);Domènech, E.(2,5);
Created: Friday, 14 July 2023, 11:12 AM
P694: Non-medical mandatory reversed and back and forth switch between infliximab and its biosimilar: Early clinical outcomes
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Ilias1*, K. Szanto2, L. Gonczi1, Z. Kurti1, P.A. Golovics3, E. Schafer3, K. Farkas2, T. Szamosi3, Z. Szepes2, T. Molnar2, A. Vincze4, P.L. Lakatos1,5

Created: Thursday, 21 February 2019, 9:14 AM
P695 Vedolizumab induction and maintenance though levels and long-term clinical and biochemical status in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Gutiérrez Casbas1, L. Sempere Robles2, R. Muñoz Pérez2, A. Rodríguez Angulo2, S. Climent3, J.I. Cameo Lorenzo2, M. Díaz3, P. Boada3, P. Más-Serrano3

Created: Thursday, 30 January 2020, 10:12 AM
P695: Attitudes and predictors of COVID-19 vaccine uptake in patients with Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Zhang, E.(1);Gupta, A.(1);Macrae, F.A.(1);Christensen, B.(1);
Created: Friday, 11 February 2022, 3:56 PM
P695: Does anticoagulation treatment increase the rate of major bleeding complications in patients with IBD and venous thromboembolism?
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Novacek1*, S. Tonko1, A. Sobala1, H. Tilg2, W. Petritsch3, W. Reinisch1, A. Mayer4, T. Haas5, O. Ludwiczek6, T. Feichtenschlager7, H. Fuchssteiner8, P. Steiner9, H. Vogelsang1, W. Miehsler10, R. Platzer11, W. Tillinger12, A. Schmid13, B. Blaha14, H. Herkner15

Created: Thursday, 21 February 2019, 9:14 AM
P695: Effectiveness and Safety of Combination Biologic or Small Molecule Therapy in Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: McShane, C.(1)*;Varley, R.(2);Fennessy, A.(3);Campion, J.(4);Ring, E.(5);Kelly, O.(5);Slattery, E.(4);Doherty, G.(6);McCarthy, J.(2);Kevans, D.(7);
Created: Friday, 14 July 2023, 11:12 AM
P695: Feasibility and safety of strictureplasties performed by laparoscopic approach for complicated Crohn’s disease: A prospective observational cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. M. Sampietro1, F. Colombo*1, A. Frontali2, C. Baldi1, L. Conti1, D. Dilillo3, P. Fiorina4, G. Maconi5, S. Ardizzone5, F. Corsi6, G. Zuccotti3, D. Foschi1

Created: Friday, 22 February 2019, 9:41 AM
P695: The risk of proximal disease extension in patients with limited ulcerative colitis in a prospective European population-based inception cohort – the ECCO-EpiCom cohort
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Burisch J.*1, Halfvarson J.2, Kupcinskas L.3, Hernandez V.4, Kaimakliotis I.5, Valpiani D.6, Pedersen N.7, Duricova D.8, Kievit L.9, Dahlerup J.F.10, Fumery M.11, Salupere R.12, Arebi N.13, Nielsen K.R.14, Giannotta M.15, Oksanen P.16, Katsanos K.H.17, Vegh Z.18, Ellul P.19, Schwartz D.20, Čuković-Čavka S.21, D'Incà R.22, Turcan S.23, Magro F.24,25,26, Goldis A.27, Langholz E.28, Lakatos P.L.18, Munkholm P.1 EpiCom Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
P696 The usefulness to treatment enhancement for the patients of ulcerative colitis with clinical remission diagnosed as Mayo endoscopic subscore 1
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Kubota Kajiwara, K. Uchiyama, Y. Azuma, R. Yasuda, S. Takayama, T. Takagi, Y. Naitoh

Created: Thursday, 30 January 2020, 10:12 AM
P696: Ambient air quality as risk factor for microscopic colitis – a Geographic Information System study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Verhaegh B.P.M.*1,2, Beijnens E.M.3, van den Heuvel T.R.A.1, Goudkade D.4, Zeegers M.P.2,5, Nawrot T.S.3, Masclee A.A.M.1,2, Jonkers D.M.A.E.1,2, Pierik M.J.1

Created: Wednesday, 20 February 2019, 10:36 AM
P696: Design and rationale for the multicentre, randomised, controlled VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jairath, V.(1,2,3)*;Zou, G.(2,3,4);Radulescu, G.(3);Sigler, J.(3);Mcfarlane, S.C.(3);Adsul, S.(5);Freire, M.(5);Peyrin-Biroulet, L.(6);Colombel, J.F.(7);Moran, G.W.(8,9);Sebastian, S.(10,11);Travis, S.(12);Vermeire, S.(13);Sandborn, W.J.(14);D'Haens, G.R.(15); Feagan, B.G.(1,2,3);
Created: Friday, 14 July 2023, 11:12 AM
P696: Faecal microbiota transplantation in ultra-refractory ulcerative colitis: Retrospective analysis in a tertiary care centre
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Guerrero García1*, A. Flores de Miguel1, E. Sánchez Rodríguez1, R. Ríos León1, G. Roy Ariño2, R. Del Campo Moreno3, A. Albillos Martínez1, A. López-Sanromán1

Created: Thursday, 21 February 2019, 9:14 AM
P696: Genetic predisposition to infliximab immunogenicity in patients with immune-mediated inflammatory diseases – secondary analyses from a randomised clinical trial
Year: 2022
Source: ECCO'22
Authors: Bjørlykke, K.(1,2);Brun, M.K.(2,3);Viken, M.K.(4,5);Stenvik, G.E.(3);Klaasen, R.A.(6);Gehin, J.E.(2,6);Warren, D.J.(6);Sexton, J.(3);Haavardsholm, E.A.(2,3);Jahnsen, J.(1,2);Lie, B.A.(2,4,5);Goll, G.L.(3);Bolstad, N.(6);Syversen, S.W.(3);Jørgensen, K.K.(1);
Created: Friday, 11 February 2022, 3:56 PM
P696: Long-term prognosis and predictive factors for surgical treatment of intestinal lesions in patients with Behcet’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Chohno*1, K. Watanabe1, T. Minagawa1, R. Kuwahara1, Y. Horio1, H. Sasaki1, T. Bando1, M. Uchino1, H. Ikeuchi1

Created: Friday, 22 February 2019, 9:41 AM
P697 Efficacy and safety of ustekinumab in Crohn’s disease: A real-world study from Australia
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P. Kakkadasam Ramaswamy, H. Moattar, E. Sawyer, J. Edwards, D. Shukla

Created: Thursday, 30 January 2020, 10:12 AM
P697: Pneumocystis jirovecii pneumonia in IBD patients treated with immunomodulator(s)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Vieujean*1, A. Moens2, K. Rothfuss3, E. Savarino4, S. Vavricka5, C. Reenaers1, M. Ferrante2, J-F. Rahier6, ECCO CONFER Investigators1

Created: Friday, 22 February 2019, 9:41 AM
P697: Association of inflammatory bowel disease and celiac disease. Experience in a hospital of the autonomous community of Madrid (Spain)
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Manceñido Marcos N.*1, Pajares Villarroya R.1, Salinas Moreno S.2, Arribas Lόpez M.R.1, Comas Redondo C.1

Created: Wednesday, 20 February 2019, 10:36 AM